SCHEMBL13201475

SCHEMBL13201475

Cc1ccc(S(=O)(=O)CNC(=O)OC(C)(C)C)cc1

nearest known ligand 0.55

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 9/20 0.55
TDP1 Q9NUW8 3/20 0.55
TP53 P04637 1/20 0.55
MAPT P10636 5/20 0.54
ADAM17 P78536 1/20 0.54
CYP1A2 P05177 1/20 0.53
CYP3A4 P08684 1/20 0.53
CYP2C9 P11712 1/20 0.53
CYP2C19 P33261 1/20 0.53
KMT2A Q03164 2/20 0.49
HPGD P15428 1/20 0.49
MEN1 O00255 1/20 0.49
CA1 P00915 8/20 0.48
CA2 P00918 8/20 0.48
CA12 O43570 5/20 0.48
CA9 Q16790 5/20 0.48
ALOX12 P18054 2/20 0.44
LMNA P02545 2/20 0.43
MAPK1 P28482 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15806525 0.86 MAPT (0.55) ALDH1A1TDP1TP53MAPTKMT2A
SCHEMBL1926110 0.85 CA1 (0.52) ALDH1A1TDP1MAPTCYP3A4CYP2C9
SCHEMBL28619945 0.81 ALDH1A1 (0.57) ALDH1A1TDP1TP53MAPTADAM17
SCHEMBL5241017 0.81 CA1 (0.57) ALDH1A1TDP1CYP3A4CYP2C9CYP2C19
SCHEMBL28578349 0.80 CA1 (0.53) ALDH1A1MAPTCYP3A4CYP2C9CYP2C19
SCHEMBL6752911 0.79 ALDH1A1 (0.66) ALDH1A1TDP1TP53MAPTADAM17
SCHEMBL11325997 0.79 ALDH1A1 (0.71) ALDH1A1TDP1TP53MAPTADAM17
SCHEMBL25848715 0.78 ALDH1A1 (0.54) ALDH1A1MAPTKMT2AHPGDMEN1
SCHEMBL23846018 0.78 NFKB1 (0.41) ALDH1A1TDP1TP53MAPTHPGD
SCHEMBL791306 0.77 CA2 (0.56) ALDH1A1TDP1MAPTKMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12053451-B2 Arginase inhibitors and their therapeutic applications Oncoarendi Therapeutics S.A. (PL) 2024-08-06 US disclosed
CN-109415387-B Arginase inhibitors and therapeutic uses thereof 昂科艾伦迪治疗法公司 2021-08-27 CN disclosed
US-10912755-B2 Arginase inhibitors and their therapeutic applications Oncoarendi Therapeutics S.A. (PL) 2021-02-09 US disclosed
EP-3452485-B1 ARGINASE INHIBITORS AND THEIR THERAPEUTIC APPLICATIONS ONCOARENDI THERAPEUTICS SA (PL) 2020-09-09 EP disclosed
US-10391077-B2 Arginase inhibitors and their therapeutic applications Oncoarendi Therapeutics S.A. (PL) 2019-08-27 US disclosed
EP-3452485-A2 ARGINASE INHIBITORS AND THEIR THERAPEUTIC APPLICATIONS Oncoarendi Therapeutics SA (PL) 2019-03-13 EP disclosed
WO-2017191130-A2 ARGINASE INHIBITORS AND THEIR THERAPEUTIC APPLICATIONS ONCOARENDI THERAPEUTICS SA (PL) 2017-11-09 WO disclosed
US-20170319536-A1 Arginase Inhibitors and Their Therapeutic Applications Oncoarendi Therapeutics S.A. (PL) 2017-11-09 US disclosed
US-20170319536-A1 Arginase Inhibitors and Their Therapeutic Applications Oncoarendi Therapeutics S.A. (PL) 2017-11-09 US disclosed
US-20170319536-A1 Arginase Inhibitors and Their Therapeutic Applications Oncoarendi Therapeutics S.A. (PL) 2017-11-09 US disclosed
WO-2017191130-A2 ARGINASE INHIBITORS AND THEIR THERAPEUTIC APPLICATIONS ONCOARENDI THERAPEUTICS SA (PL) 2017-11-09 WO disclosed
US-7772263-B2 Compounds for the treatment of inflammatory disorders SCHERING CORPORATION (US) 2010-08-10 US disclosed
US-20090156586-A1 COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS SCHERING CORPORATION 2009-06-18 US disclosed
US-7524842-B2 Compounds for the treatment of inflammatory disorders SCHERING CORPORATION (US) 2009-04-28 US disclosed
US-20070197564-A1 Compounds for the treatment of inflammatory disorders SCHERING CORPORATION 2007-08-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090156586-A1 COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS ADAMTS1, ADAMTS13, ADAMTS7 ALDH1A1 1372/4885TDP1 1851/4885TP53 1812/4885
US-10391077-B2 Arginase inhibitors and their therapeutic applications ARG1, ARG2, ARGLU1 ALDH1A1 675/4885TDP1 829/4885TP53 1854/4885
US-20170319536-A1 Arginase Inhibitors and Their Therapeutic Applications ARG1, ARG2, ARGLU1 ALDH1A1 675/4885TDP1 829/4885TP53 1854/4885
US-20070197564-A1 Compounds for the treatment of inflammatory disorders ADAMTS1, ADAMTS13, ADAMTS7 ALDH1A1 1372/4885TDP1 1851/4885TP53 1812/4885
US-10912755-B2 Arginase inhibitors and their therapeutic applications ARG1, ARG2, ARGLU1 ALDH1A1 675/4885TDP1 829/4885TP53 1854/4885
US-12053451-B2 Arginase inhibitors and their therapeutic applications ARG1, ARG2, ARGLU1 ALDH1A1 675/4885TDP1 829/4885TP53 1854/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.